Real-time, recursive, fact-first architecture reduces AI-generated "note bloat" by 65 percent and minimizes post-visit edits - transforming passive documentation into…
The TUXEDO-3 trial is the first study to evaluate the intracranial and extracranial efficacy and safety of a novel anti-cancer…